Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma

NCT07200102 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Selinexor

Sponsor

Washington University School of Medicine

Collaborators

[object Object]